Telisotuzumab vedotin (ABBV-399), 2.7 mg/kg once every three weeks, has been evaluated in the LUNG-MAP Sub-Study S1400K in 23 patients with previously treated c-MET-positive, stage IV squamous recurrent NSCLC [38]. Here, MET is linked to non-small cell lung carcinoma.